Clinical trials: Neoplasms, Metastatic
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.
- Trial name
- NCT04380753
- Testing
- AMG 510
- Where
- 4 sites in Hong Kong, Taiwan
- Volunteers
- 12 people
- Sponsor
- Amgen
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Evaluation of Barriers to Cancer Care Delivery and Outcomes for Women of Color With Metastatic Breast Cancer
This study evaluates disparities and barriers in cancer care delivery and outcomes in women of color by identifying socioeconomic variables that may be related to the inequity.
- Trial name
- NCT06206239
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Thomas Jefferson University
Pancreatic Cancer
Study of Sirolimus in Patients With Advanced Pancreatic Cancer
Pancreatic cancer is a highly malignant tumor of the digestive system.In China, the annual mortality/morbidity of pancreatic cancer is as high as 0.88:1, and the morbidity and mortality are still on the rise.
- Trial name
- NCT03662412
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Neoplasms, Breast
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors overexpress the…
- Trial name
- NCT00347919
- Testing
- pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, lapatinib (GW572016) 1000 mg
- Where
- 84 sites in United States, Canada and 14 more
- Volunteers
- 189 people
- Sponsor
- GlaxoSmithKline
Neoplasm Metastasis
Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer
The purpose of this study is to evaluate the safety of administering a single dose of trastuzumab into the artery for the treatment of brain metastasis(es) from HER2/neu positive breast cancer.
- Trial name
- NCT02571530
- Testing
- Intra-arterial Cerebral Infusion of Trastuzumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Northwell Health
Nasopharyngeal Neoplasms
Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
Primary objective: To evaluate the response rate of biweekly gemcitabine and oxaliplatin (the GEMOX regimen) in the first line treatment of metastatic or recurrent nasopharyngeal carcinoma.
- Trial name
- NCT00436800
- Testing
- Gemcitabine, Oxaliplatin
- Where
- Hong Kong
- Volunteers
- 41 people
- Sponsor
- Sanofi
Metastatic Cancer
Exercise Therapy in Radiation Therapy
The purpose of this study is to evaluate exercise therapy as a method for potentially improving radiation therapy treatment toxicities for metastatic cancer patients receiving radiation therapy.
- Trial name
- EXERT (NCT03905356)
- Testing
- Exercise Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Milton S. Hershey Medical Center
Prostate Cancer
Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer
This interventional prospective multicenter international study will include 54 patients with regionally metastatic (i.e. cN1 cM0) prostate cancer according to the NCCN criteria.
- Trial name
- WARP (NCT07591051)
- Testing
- weekly CT or MR online adaptive definitive SBRT
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 54 people
- Sponsor
- University of Zurich
Head and Neck Squamous Cell Carcinoma (HNSCC)
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Nivolumab is an antibody (a type of human protein) that is designed to boost your body's immune system. It does this by allowing immune cells to grow and fight the cancer.
- Trial name
- NCT02684253
- Testing
- Nivolumab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 6 sites in United States
- Volunteers
- 65 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer
This prospective observational study will evaluate the use in clinical practice, efficacy and safety of Avastin (bevacizumab) in combination with paclitaxel in first line in patients with HER2-negative metastatic breast cancer.
- Trial name
- NCT01661153
- Where
- 2 sites in Croatia
- Volunteers
- 16 people
- Sponsor
- Hoffmann-La Roche
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy and in combination with other cancer therapies in adult study participants with advanced or metastatic solid tumors.
- Trial name
- ORCHID-1 (NCT05716295)
- Testing
- MDK-703, Checkpoint Inhibitor, Immune
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Medikine, Inc.
Breast Cancer
A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ，previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens…
- Trial name
- NCT04400695
- Testing
- RC48-ADC, Paclitaxel Injection, Docetaxel Injection
- Where
- China
- Volunteers
- 366 people
- Sponsor
- RemeGen Co., Ltd.
Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.
- Conditions
- Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer, Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
- Trial name
- NCT01209195
- Testing
- MM-121, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Merrimack Pharmaceuticals
Metastatic Colorectal Cancer
An Observational Study, Called RegoFlex EU, to Learn More About the Use of Stivarga at Reduced Doses as Recommended (Flexible Dosing) to Treat People With Metastatic Colorectal Cancer in Real World Settings in Europe
This is an observational study in which data from patients with metastatic colorectal cancer in three European countries who received STIVARGA® (regorafenib), are collected.
- Trial name
- RegoFlex EU (NCT05551039)
- Testing
- Retrospective patient chart review
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Bayer
Breast Cancer
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
This is a phase 1b/2 study of the safety and efficacy of sapanisertib (MLN0128) in combination with exemestane or fulvestrant therapy in women with estrogen receptor positive/human epidermal growth factor receptor 2 negative…
- Trial name
- NCT02049957
- Testing
- Sapanisertib, Fulvestrant, Exemestane
- Where
- 40 sites in United States, Belgium and 1 more
- Volunteers
- 118 people
- Sponsor
- Calithera Biosciences, Inc
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
This is an open-label, multicenter Phase II clinical study aimed at evaluating the tolerability, safety, efficacy, PK profile, and immunogenicity of QLS31905 for Injection combined with QL2107 Injection and XELOX regimen in the…
- Trial name
- NCT06942767
- Testing
- QLS31905 for Injection, QL2107 Injection, Oxaliplatin Injection
- Volunteers
- 100 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway
This study is a randomized prospective clinical trial of women with metastatic breast cancer. The purpose of the study is to test if an intervention of regular physical activity review and physical activity goal setting will…
- Trial name
- NCT01653366
- Testing
- Physical Activity Goal Setting
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, NSCLC
- Trial name
- NCT05753722
- Testing
- PRTH-101, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 79 people
- Sponsor
- Incendia Therapeutics
Gastric Cancer
IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma
This is a phase I, multi-center clinical trial to evaluate the safety, tolerability, antitumor activities and pharmacokinetics of IN10018 as monotherapy or in combination with docetaxel in previously-treated locally advanced or…
- Trial name
- NCT05327231
- Testing
- IN10018, Docetaxel
- Where
- 8 sites in China
- Volunteers
- 33 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
This early phase I trial studies the effect of pembrolizumab and lenvatinib in treating patients with gastroesophageal adenocarcinoma that has spread to other places in the body (advanced/metastatic) or cannot be removed by…
- Conditions
- Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT05041153
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.